Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia

Haematologica

Volumn 95, Issue 5, 2010, Pages 852-853

  Suttorp, Meinolf ^a   Thiede, Christian ^a   Tauer, Josephine T ^a   Range, Ursula ^a   Schlegelberger, Brigitte ^b   von Neuhoff, Nils ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chronic myeloid leukemia; E14a2 versus e13a2 transcript; Pediatrics

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ADOLESCENT; CANCER CHEMOTHERAPY; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; LETTER; MALE; MOLECULAR GENETICS; OUTCOME ASSESSMENT; PRESCHOOL CHILD; SCHOOL CHILD; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; INFANT; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PYRIMIDINES; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 77952304387     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.019224     Document Type: Letter

References (8)

1. Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, et al. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica. 2009;94(10):1362-7.
2. Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood. 2004;104(9):2655-60.
3. Millot F, Guilhot J, Nelken B, Leblanc T, De Bont ES, Bekassy AN, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia. 2006;20(2):187-92.
4. Suttorp M. Innovative approaches of targeted therapy for chronic myeloid leukaemia of childhood in combination with paediatric haematopoietic stem cell transplantation (Review). Bone Marrow Transplant. 2008;42(Suppl.2):S40-S46.
5. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors - review and recommendations for "harmonizing" current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37
6. Adler R, Viehmann S, Kuhlisch E, Martiniak Y, Röttgers S, Harbott J, et al. Correlation of BCR/ABL Transcript Variants with Patients' Characteristics in Childhood Chronic Myeloid Leukaemia. Eur J Haematol. 2008;82(2):112-8
7. Jonsson S, Olsson B, Ohlsson C, Lorentzon M, Mellstrom D, Wadenvik H. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia Haematologica. 2008;93(7):1101-3.
8. Schmid H, Jaeger BAS, Lohse J, Suttorp M. Longitudinal growth retardation in a prepupertal girl with chronic myeloid leukemia on long-term imatinib treatment. Haematologica. 2009;94(8): 1177-9.